Ryan Rader, MD

Though scientifically promising, PD-1 inhibitors are simply not safe with CDK4/6i. #bcsm CheckMate7A8= nivo/palbo/AI w grade 3/4 hepatic AEs [n = 3], grade 3 rash and grade 2 immune-mediated pneumonitis [n = 1], grade 3 febrile neutropaenia [n = 1]). thebreastonline.com/article/S0960-…

@thriftycars at SFO. 2 hour line to get to the check-in desk to be told they didn’t have a car available right now. Have to wait another 45-60 minutes, already been another hour. Is it reasonable to be waiting 3+ hours for a rental car? Because I don’t think so.

First Line CDK4/6 median PFS and OS to date across trials… #bcsm

@RyanRaderMD @precisca_

New review on Available Systemic Treatments and Emerging Therapies for #BreastCancer Brain Metastases from @RyanRaderMD @CareyAnders1 @nlinmd and @drsarahsam. 👉pubmed.ncbi.nlm.nih.gov/37071254/

@AtiehTahaniDO @NAbuhadra @NAbuhadra how could you?!

Mine’s better. ⁦@RyanRaderMD⁩ ⁦@NAbuhadra⁩ ❤️❤️

One of the true treats of in-person conferences is seeing blasts from the past. @NAbuhadra is one of the kindest, hilarious and engaging people. It doesn’t hurt that she’s a brilliant breast oncologist at MSKCC! Thrilled to reconnect, Nour! #ASCO22

@hoperugo discusses Tropics02 Sacituzumab versus Physician Choice chemotherapy in heavily pretreated HR+/HER2- BC. PFS 5.5 v 4.0 m (HR 0.66) OS immature A positive study. Biomarker needed. Trop2 level analysis will be interesting. #bcsm #ASCO2022 @OncoAlert

Heading to the airport for my first in-person conference since COVID! #ASCO22 Hoping to learn the latest and greatest, reconnect with old friends.

📣 Heme Onc Fellows searching for jobs in academia, see👇🏼! Sign up to meet with outstanding early career faculty & get invaluable guidance on the job search! Retweet to share w/other fellows! #ASCO22 @dr_simkins @RyanRaderMD @YuWeiChenMD @MadisonConces @LoganRoofMD @KunalDesaiMD

@ogutierrez89 @elishaPA_C @firstgendocs @LaurenGranat @DulceMariaMPH @medpedshosp @EYMD_ @gyfjiang @JeydithMd @himanshu_deshwa Done

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy #cancer @oncoalert ascopubs.org/doi/pdf/10.120… @ASCO @JCOOP_ASCO

A quick snapshot of Her2low #SABCS21

What a ride! Four intense days of presentations, discussions, insights & networking. @SABCSSanAntonio never disappoints. Here’s my 5 take-home messages from these days. As usual, these are not exhaustive, as #SABCS21 was truly full of amazing science and striking advancements.

Congratulations ⁦@dbasali⁩ for your #SABCS21 presentation and your ongoing work to better understand disparities in breast cancer outcomes! #CleClinicCancer ⁦@CleClinicMD⁩ ⁦@CCF_IMCHIEFS⁩

Studies have shown lower risks of GI bleeding on apixaban when compared to rivaroxaban. CVS Caremark is planning to take apixaban off formulary and out of the hands of patients. We should not give patients fewer options. (No conflicts of interest)

SOFT and TEXT 12-13 yr med FU confirms benefit of EXE+OFS in high risk HER2 neg HR+ BC in premen women. 10% benefit in survival in. <35yo with T/OFS v T and 15% with E/OFS @OncoAlert

She was a senior, he was an intern… and the rest is history. Another CCF power-couple got married this weekend! 👰🏻‍♀️🤵🏼From the wards to the altar, married by one of ours @danielmarcosmd; CCF family celebration! 🍾@BryceMontane @RyanRaderMD @ErinCovert22 @J_YoonYoon

More than 99.99% of fully vaccinated people have not had a breakthrough case of Covid-19 resulting in hospitalization or death, a CNN analysis shows cnn.it/3s5YVJS

Affordable Care Act and Cancer Survivors' Financial barriers in cancer survivors age 18-64 years significantly improved following ACA implementation ascopubs.org/doi/full/10.12… @ASCO_pubs @ASCO @OncoAlert